India Share Brokers | Equity Trading India | Derivative Trading in India | Share Brokers in India

Markets Navigation

Company Info.

Parmax Pharma Ltd.

Balance Sheet - Standalone

Market Cap.(`)	15.08 Cr.	P/BV	-23.61	Book Value (`)	-1.71
52 Week High/Low ( ` )	54/25	FV/ML	10/1	P/E(X)	0.00
Book Closure	30/09/2024	EPS (`)	0.00	Div Yield (%)	0.00

(` in Crs.)

You can view the Standalone Balance Sheet for the last 5 years.

Particulars	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Months	12	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR	AR
FaceValue	10.00	10.00	10.00	10.00	10.00
No. of Equity Shares (in Lacs)	51.01	51.01	51.01	51.01	51.01

EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital	4.45	4.45	4.45	4.45	4.45
Total Share Capital	4.45	4.45	4.45	4.45	4.45

Reserves and Surplus	-4.38	1.40	1.51	1.37	0.61
Total Reserves and Surplus	-4.38	1.40	1.51	1.37	0.61
Total Shareholders Funds	0.07	5.86	5.96	5.82	5.06

NON-CURRENT LIABILITIES
Long Term Borrowings	5.91	4.48	4.52	5.43	5.03
Deferred Tax Liabilities [Net]	0.14	0.14	0.18	0.23	0.07
Total Non-Current Liabilities	6.05	4.62	4.70	5.66	5.11

CURRENT LIABILITIES
Trade Payables	7.39	4.66	5.52	9.92	9.92
Other Current Liabilities	1.60	1.50	0.86	0.49	0.24
Short Term Provisions	0.23	0.97	0.94	0.84	0.73
Total Current Liabilities	9.21	7.14	7.32	11.25	10.89

Total Capital And Liabilities	15.33	17.61	17.97	22.73	21.06

ASSETS
NON-CURRENT ASSETS
Tangible Assets	9.27	9.50	10.44	10.84	9.64
Capital Work-In-Progress	0.10	0.00	0.00	0.00	0.00
Fixed Assets	9.38	9.50	10.44	10.84	9.64
Non-Current Investments	0.00	0.00	0.00	0.20	0.20
Long Term Loans And Advances	0.18	0.19	0.18	0.16	0.20
Other Non-Current Assets	0.00	0.40	0.79	1.19	1.58
Total Non-Current Assets	9.56	10.08	11.42	12.39	11.62


CURRENT ASSETS
Inventories	2.39	4.31	2.85	3.95	2.72
Trade Receivables	1.82	0.62	0.68	1.65	3.30
Cash And Cash Equivalents	0.05	0.41	1.05	2.55	1.77
Short Term Loans And Advances	1.51	2.19	1.98	2.19	1.65
Total Current Assets	5.77	7.53	6.56	10.34	9.44

Total Assets	15.33	17.61	17.97	22.73	21.06

OTHER INFORMATION

CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities	0.00	1.00	1.00	0.00	0.00

NON-CURRENT INVESTMENTS
Non-Current Investments Unquoted Book Value	0.00	0.00	0.00	0.20	0.20

Parmax Pharma Ltd.

Ratio Analysis - Standalone

Market Cap.(`)	15.08 Cr.	P/BV	-23.61	Book Value (`)	-1.71
52 Week High/Low ( ` )	54/25	FV/ML	10/1	P/E(X)	0.00
Book Closure	30/09/2024	EPS (`)	0.00	Div Yield (%)	0.00

You can view the Standalone Ratio Analysis for the last 5 years.

Particulars	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Months	12	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR	AR
FaceValue	10.00	10.00	10.00	10.00	10.00

PER SHARE RATIOS

Basic EPS (Rs.)	-11.33	-0.28	0.38	2.02	1.15
Diluted EPS (Rs.)	-11.33	-0.28	0.38	2.02	1.15
Cash EPS (Rs.)	-9.14	3.99	4.66	6.06	3.23
Book Value[Excl.RevalReserv]/Share (Rs.)	0.15	13.15	13.38	13.07	11.38
Book Value[Incl.RevalReserv]/Share (Rs.)	0.15	13.15	13.38	13.07	11.38
Revenue From Operations / Share (Rs.)	24.83	34.65	41.00	58.87	47.03
PBDIT / Share (Rs.)	-7.46	5.15	5.89	7.87	4.19
PBIT / Share (Rs.)	-11.31	0.93	1.55	3.51	1.93
PBT / Share (Rs.)	-12.71	0.10	0.68	2.71	1.64
Net Profit / Share (Rs.)	-12.98	-0.23	0.31	1.69	0.96

PROFITABILITY RATIOS

PBDIT Margin (%)	-30.05	14.87	14.36	13.37	8.90
PBIT Margin (%)	-45.54	2.69	3.77	5.96	4.09
PBT Margin (%)	-51.17	0.29	1.66	4.61	3.49
Net Profit Margin (%)	-52.28	-0.67	0.77	2.87	2.04
Return on Networth / Equity (%)	-8146.36	-1.77	2.37	12.96	8.46
Return on Capital Employeed (%)	-82.27	3.96	6.46	13.60	8.43
Return On Assets (%)	-37.69	-0.59	0.78	3.31	2.03
Long Term Debt / Equity (X)	83.26	0.76	0.75	0.93	0.99
Total Debt / Equity (X)	83.26	0.76	0.75	0.93	0.99
Asset Turnover Ratio (%)	0.67	0.86	0.89	1.20	1.03

LIQUIDITY RATIOS

Current Ratio (X)	0.62	1.05	0.89	0.91	0.86
Quick Ratio (X)	0.36	0.45	0.50	0.56	0.61
Inventory Turnover Ratio (X)	2.10	1.54	1.97	4.02	3.35

COVERAGE RATIOS

Interest Coverage Ratio (%)	-5.34	6.22	6.79	9.89	14.64
Interest Coverage Ratio (Post Tax) (%)	-8.30	0.71	1.37	3.13	4.37

VALUATION RATIOS

Enterprise Value (Cr.)	18.53	17.59	21.65	18.69	10.39
EV / Net Operating Revenue (X)	1.68	1.14	1.19	0.71	0.49
EV / EBITDA (X)	-5.58	7.67	8.26	5.33	5.57
MarketCap / Net Operating Revenue (X)	1.15	0.87	0.99	0.60	0.34
Price / BV (X)	179.12	2.31	3.05	2.72	1.41
Price / Net Operating Revenue (X)	1.15	0.87	0.99	0.60	0.34
EarningsYield	-0.45	-0.01	0.01	0.04	0.06

Attention Investors : “Prevent unauthorized transactions in your account ? Update your Mobile Numbers/Email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your Mobile/Email at the end of the day. Issued in the interest of Investors” ***** No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. | | ***** KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. | "Revised guidelines on margin collection ==> 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. | 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | 3. Pay 20% upfront margin of the transaction value to trade in cash market segment. | 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. | 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors" | ***** MEMBERS : SEBI Regn. No: NSE, BSE: INZ000176636 ; MCX : INZ000057535; SEBI Research Analyst Regn No: INH200000337; AMFI Regn No. 77624; Depository Participant : CDSL : IN-DP-CDSL-379-2006 DP ID : 12047600 | For any Grievance mail to : grievance@sharewealthindia.com | For any DP Grievance mail to : dpgrievance@sharewealthindia.com. | Grievance with SEBI : https://scores.gov.in/scores/Welcome.html

Share Wealth

Parmax Pharma Ltd.

Balance Sheet - Standalone

Parmax Pharma Ltd.

Ratio Analysis - Standalone